WITHDRAWN, NO REPLACEMENT
| ||Format||Pages||Price|| |
|3||$45.60||  ADD TO CART|
This practice covers procedures used for the detection of mycoplasma contamination by indirect DNA staining.
Formerly under the jurisdiction of Committee E55 on Manufacture of Pharmaceutical Products, this practice was withdrawn in August 2014. This standard was withdrawn without replacement due to its limited use by the industry.
1.1 This practice covers procedures used for the detection of mycoplasma contamination by indirect DNA staining.
1.2 This practice does not cover direct methods for the detection of mycoplasma or other indirect methods such as enzymatical detection or DNA probes.
1.3 This practice does not cover methods for the identification of mycoplasma organisms.
1.4 The values stated in SI units are to be regarded as the standard. The values given in parentheses are for information only.
This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.
2. Referenced Documents (purchase separately) The documents listed below are referenced within the subject standard but are not provided as part of the standard.
E1531 Practice for Detection of Mycoplasma Contamination of Cell Cultures by Growth on Agarose Medium
E1532 Practice for Detection of Mycoplasma Contamination of Cell Cultures by Use of Bisbenzamide DNA-Binding Fluorochrome
E1536 Practice for Detection of Mycoplasma Contamination of Bovine Serum by Large Volume Method
ASTM E1533-00(2006), Standard Practice for Indirect Detection of Mycoplasma in Cell Culture by 4`-6-Diamidino-2-2 Phenylindole (DAPI) Staining (Withdrawn 2014), ASTM International, West Conshohocken, PA, 2006, www.astm.orgBack to Top